MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Apomorphine"

  • 2024 International Congress

    When Off Can Cost Life: Myocardial Infarction Due to Spontaneous Coronary Dissection as a Catastrophic Manifestation in Advanced Parkinson’s Disease.

    S. Poveda, T. Lopez, B. Pascual Sedano, A. Campolongo (Bogotá, Colombia)

    Objective: Describe a patient with PD who suffered an acute myocardial infarction during a severe OFF period. Background: Advanced PD is characterized by complications including…
  • 2024 International Congress

    Personality may influence the response to apomorphine infusion in Parkinson’s disease patients

    M. Boussac, E. Harroch, C. Barthelemy, F. Ory-Magne, C. Leung, M. Fabbri, C. Arbus, C. Brefel-Courbon (Toulouse, France)

    Objective: to evaluate the impact of personality on quality-of-life (QoL) amelioration after treatment by Continuous Subcutaneous Apomorphine Infusion (CSAI) in Parkinson’s disease (PD). Background: PD…
  • 2024 International Congress

    Continuous Subcutaneous Apomorphine Infusion (CSAI) Improved Confidence When Engaging in Everyday Activities: Survey of InfusON Study Participants

    P. Agarwal, A. Formella, N. Crouse, A. Breiteneicher, M. Grall (Kirkland, USA)

    Objective: Evaluate participants' perceptions of their confidence when engaging in daily activities and interpersonal relationships while using CSAI therapy, relative to the period before CSAI…
  • 2024 International Congress

    Patient Experiences Initiating Continuous Subcutaneous Apomorphine Infusion (CSAI): An Interview-Based Survey of InfusON Study Participants

    P. Agarwal, N. Crouse, A. Breiteneicher, M. Formella (Kirkland, USA)

    Objective: Obtain patient feedback on experiences initiating and using continuous subcutaneous apomorphine infusion (CSAI). Background: Previously reported data from the ongoing InfusON study demonstrated that…
  • 2024 International Congress

    Continuous Subcutaneous Apomorphine Infusion for Parkinson Disease Motor Fluctuations: Long-Term Data from the Ongoing InfusON Extension Study

    P. Lewitt, S. Isaacson, A. Espay, S. Reyes, A. Formella, G. Ceresoli-Borroni (Detroit, USA)

    Objective: Evaluate outcomes (up to 3 years) from the ongoing Extension Period of the InfusON study (NCT02339064) of continuous subcutaneous apomorphine infusion (CSAI). Background: Primary…
  • 2024 International Congress

    Overview of Phase 3 Trials of Continuous Subcutaneous Apomorphine Infusion for PD Patients with Motor Fluctuations

    R. Pahwa, T. van Laar, K. Dashtipour, G. Ceresoli-Borroni (Kansas City, USA)

    Objective: Review available efficacy data from Phase 3 studies assessing continuous subcutaneous apomorphine infusion (CSAI) for patients with PD experiencing motor fluctuations. Background: Despite decades…
  • 2024 International Congress

    Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment

    D. Kremens, R. Hauser, A. Formella, M. Joshi, M. Grall (Philadelphia, USA)

    Objective: Evaluate the effect of continuous subcutaneous apomorphine infusion (CSAI) on daily periods of OFF time and Good ON time (ON without troublesome dyskinesia) in…
  • 2024 International Congress

    Baseline Variables Associated with Apomorphine Sublingual Film Retention

    J. Kassubek, J. Schwarz, L. López Manzanares, M. Fonseca, C. Denecke Muhr (Ulm, Germany)

    Objective: The aim of this analysis was to identify the baseline variables that differ between patients who completed Study CTH-301 and those who discontinued during…
  • 2024 International Congress

    Oropharyngeal Adverse Events in Parkinson’s Patients with Motor Fluctuations Treated with Apomorphine Sublingual Film

    L. Wojtecki, F. Moreira, E. Cubo, M. Fonseca, G. Harrison-Jones, C. Denecke Muhr (Düsseldorf, Germany)

    Objective: This post-hoc analysis of Study CTH-301 assessed the occurrence of oropharyngeal treatment-emergent adverse events (TEAEs) in patients with Parkinson’s disease included in this study.…
  • 2024 International Congress

    Safety and Efficacy of Sublingual Apomorphine in Parkinson’s Patients with or without Concomitant Dopamine Agonists Use

    D. Santos Garcia, W. Jost, M. José Martí, M. Fonseca, C. Denecke Muhr, I. Pijuan (A Coruña, Spain)

    Objective: This post-hoc analysis of Study CTH-301 aimed to assess the safety and efficacy of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease with…
  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley